83,000 DEATHS AND 1.7 MILLION INJURIES GLOBALLY HAVE BEEN LINKED TO INADEQUATE MEDICAL DEVICE TESTING .
H E A L T H I N S I G H T S
Sheena Macpherson , CEO of adsilico on underserved communities , further exacerbating existing health inequities .
Furthermore , device manufacturers themselves face significant financial risks from a lack of consideration of diversity in device development . When devices fail or perform poorly in underrepresented populations after-market release , companies face costly recalls , litigation and damage to their reputation . The resources required to address these issues post-market far exceed the cost of more inclusive testing during development .
Virtual solution
Amid this crisis , a revolutionary solution is emerging – virtual patients . Advanced computational techniques can now create digital , diverse and representative virtual patient populations that capture the full spectrum of human anatomical and physiological variation . This approach , known as in silico trials ( ISTs ), offers a way to test medical devices across a much broader range of patient characteristics than traditional clinical trials allow .
83,000 DEATHS AND 1.7 MILLION INJURIES GLOBALLY HAVE BEEN LINKED TO INADEQUATE MEDICAL DEVICE TESTING .
The initial wave of virtual patient innovation has focused on creating digital twins of individual patients . While this represented an important step forward , achieving true diversity at scale requires a more sophisticated approach .
A pioneering new computational medicine company in the UK , adsilico , has recently
18 www . intelligenthealth . tech